Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accounts Payables (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Accounts Payables for 5 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 0.54% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2025, down 0.54%, and an annual FY2025 reading of $2.0 million, down 0.54% over the prior year.
  • Accounts Payables was $2.0 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $6.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $9.0 million in Q2 2025 and bottomed at $648000.0 in Q2 2023.
  • Average Accounts Payables over 5 years is $4.0 million, with a median of $2.6 million recorded in 2021.
  • Peak annual rise in Accounts Payables hit 1040.9% in 2024, while the deepest fall reached 75.27% in 2024.
  • Year by year, Accounts Payables stood at $1.9 million in 2021, then surged by 322.86% to $7.9 million in 2022, then grew by 4.39% to $8.2 million in 2023, then crashed by 75.27% to $2.0 million in 2024, then dropped by 0.54% to $2.0 million in 2025.
  • Business Quant data shows Accounts Payables for KNSA at $2.0 million in Q4 2025, $6.1 million in Q3 2025, and $9.0 million in Q2 2025.